Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.71 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097616 | 1.00 | GRIA2 (1.00) | GRIA2KCNH2KDM1A | |
| SCHEMBL4097619 | 1.00 | GRIA2 (1.00) | GRIA2KCNH2KDM1A | |
| SCHEMBL4958828 | 0.83 | GRIA2 (1.00) | GRIA2KCNH2 | |
| SCHEMBL4168264 | 0.81 | GRIA2 (0.68) | GRIA2KCNH2KDM1A | |
| SCHEMBL4168262 | 0.81 | GRIA2 (0.68) | GRIA2KCNH2KDM1A | |
| SCHEMBL4168267 | 0.81 | GRIA2 (0.68) | GRIA2KCNH2KDM1A | |
| SCHEMBL14456064 | 0.79 | GRIA2 (0.72) | GRIA2KCNH2 | |
| SCHEMBL4104365 | 0.79 | GRIA2 (0.77) | GRIA2KCNH2 | |
| SCHEMBL4104368 | 0.79 | GRIA2 (0.77) | GRIA2KCNH2 | |
| SCHEMBL4104372 | 0.79 | GRIA2 (0.77) | GRIA2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | claimed |
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| WO-2007090840-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GRIN2C, GRIN1, OXER1 | GRIA2 27/4885KCNH2 1331/4885KDM1A 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.